The Epstein-Barr virus (EBV) is incredibly common, affecting about 95% of adults. Most people don’t even notice it’s there. However, this virus is more than just a minor inconvenience. Once it enters the body, it can stick around for life, and is linked to various serious health issues, including certain cancers and multiple sclerosis.
Recently, researchers at the Fred Hutchinson Cancer Center and the University of Washington made exciting strides. They developed antibodies that target two proteins found on EBV. These proteins play a crucial role in how the virus invades B cells, which are essential for our immune response. By blocking these proteins, the antibodies could prevent EBV from entering B cells, potentially stopping the virus before it has a chance to cause harm.
In their experiments with specially bred mice, one of the newly created antibodies successfully protected against EBV infection. This is significant because finding specific antibodies for EBV has been challenging. Most viruses have clear target areas, but EBV can attach itself to nearly all B cells, making it tough to pinpoint effective defenses.
Andrew McGuire, a biochemist involved in the study, highlighted how difficult this problem has been and the innovative methods their team used to advance research. The researchers focused on two EBV proteins, gp350 and gp42, producing antibodies that showed promise in the lab.
Crystal Chhan, another scientist on the project, expressed her excitement about the breakthrough. This research not only identified important antibodies for EBV but also opened doors for discovering protective antibodies against other pathogens.
EBV often shows itself first as infectious mononucleosis or “mono,” and then goes into hiding in the body. This dormant phase can turn dangerous, especially for people with weakened immune systems, like those receiving organ or bone marrow transplants. In these cases, EBV can lead to complications like post-transplant lymphoproliferative disorders (PTLD), where B cells can multiply uncontrollably, leading to life-threatening conditions.
The new antibodies could have a significant impact on these patients. By potentially preventing EBV reactivation, the risk of PTLD might decrease, making transplants safer, especially for children who may not yet have been exposed to the virus. Rachel Bender Ignacio, an infectious disease physician, noted that reducing EBV infections could lessen the need for immunosuppression—a critical concern in transplant medicine.
While this research is promising, more work is needed before it reaches clinical application. Scientists are already exploring EBV vaccines, which could offer another layer of protection in the future.
This latest advancement against EBV not only shows progress in tackling a widespread virus but also fuels optimism for better health outcomes for those at risk. For further reading, you can check out the findings published in Cell Reports Medicine here.
Source link
MSFT Content
